Berninamycin A is a cyclic thiopeptide antibiotic first isolated from S. bernensis. It inhibits protein biosynthesis in Gram positive bacteria through binding with ribosomal subunits. Cyclic thiopeptide antibiotics, including berninamycin A, induce the transcriptional activator TipA in Streptomyces.[Cayman Chemical]
Berninamycin A is an antibiotic discovered in 1976 from a strain of Streptomyces. Berninamycin A is a macrocyclic "peptide" comprising atypical amino acids linked to thiazole and oxazoles. Chemically very complex, berninamycin A is an inducer of tipA, a gene that controls the bacterial transcription regulators, TipAL and TipAS, that are central to multidrug resistance. Berninamycin A is closely related to siomycin, a recently discovered inhibitor of oncogenic transcription factor, FoxM1.
berninamycin a is a macrocyclic thiopeptide antibiotic first isolated from s. bernensis [1]. thiopeptides are sulfur containing highly modified macrocyclic antibiotics with a central pyridine/tetrapyridine/dehydropiperidine ring with up to three thiazole substituents on positions 2, 3 and 6. thiazole antibiotics thiostrepton behaves as proteasome inhibitor in mammalian tumor cells. berninamycin showed no proteasome inhibitory activity [2]. it has been reported that the action mode of berninamycin on bacterial protein synthesis was related to that of a dissimilar compound thiostrepton. the antibiotics could bind to the complex of 23s rna with protein l11 and both affect multiple functions of the ribosomal a site [3]. berninamycin a was involved in inducing the transcriptional activator tipa in streptomyces [4].
This fungal antibiotic (FW = 1146.12 g/mol; CAS 58798-97-3; Soluble in DMSO), also known as Antibiotic U27810, from Streptomyces bernensis inhibits protein biosynthesis by binding to a complex formed by ribosomal 23S and the L11 protein, thereby disrupting the function of the ribosome’s A site and inhibiting protein synthesis in Gram-positive bacteria. In this respect, it has the same mode of action as thiostrepton. Streptomyces bernensis and Streptomyces azureus, which produce berninamycin and thiostrepton, respectively, possess similar ribosomal RNA methylases that mediate specific pentose-directed methylation of 23S ribosomal RNA, rendering the modified ribosomes resistant to these antibiotics.
[1] lau r c m, rinehart k l. berninamycins b, c, and d, minor metabolites from streptomyces bernensis[j]. the journal of antibiotics, 1994, 47(12): 1466-1472.
[2] pandit b, bhat u g, gartel a l. proteasome inhibitory activity of thiazole antibiotics[j]. cancer biology & therapy, 2011, 11(1): 43-47.
[3] j. thompson, e. cundliffe and m. j. r. stark. the mode of action of berninamycin and mechanism of resistance in the producing organism, streptomyces bernensis. j.gen.microbiol. 128(4), 875-884 (1982).
[4]. m. l. chiu, m. folcher, t. katoh, et al. broad spectrum thiopeptide recognition specificity of the streptomyces lividans tipal protein and its role in regulating gene expression. the journal of biological chemisty 274(29), 20578-20586 (1999).
